{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"80.6","upperLimit":"93.9","value":"89.0"},{"groupId":"OG001","lowerLimit":"50.8","upperLimit":"98.7","value":"90.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"Outcome Measure was pre-specified to summarize data per investigator assessment with respect to subject's vital/survival status is presented in the RRF and irrespective of iWWM 3rd or 6th criteria. Kaplan-Meier (K-M) estimates at a certain time (ex. all subjects complete Cycle 27) provides the estimated percentage of the subjects who are still alive by the given time over all patients at risk.","dispersionType":"95% Confidence Interval","groups":[{"description":"100 mg BID N=87 + 200 mg QD N= 5","id":"OG000","title":"Previously Treated (N=92)"},{"description":"100 mg BID N= 13 + 200 mg QD N=1","id":"OG001","title":"Treatment Naive (N=14)"}],"paramType":"NUMBER","populationDescription":"In the original protocol, previously treated subjects were planned to be randomized 1:1 into 2 cohorts: Cohort 1 to receive Acala 100 mg BID for 28 days and Cohort 2 to receive Acala 200 mg once daily (QD) for 28 days. After enrollment started, the dose regimen was amended. The 200 mg QD dose was eliminated, and subjects who were enrolled under the original protocol and received treatment with 200 mg QD were switched to 100 mg BID. Results are combined.","reportingStatus":"POSTED","timeFrame":"Primary analysis occur when all subjects have completed Cycle 27 or have discontinued before Cycle 27.","title":"Overall Survival (OS) of Acalabrutinib by Investigator","type":"SECONDARY","unitOfMeasure":"Percentage of subjects"}